tAnGo Trial: Evaluating Gemcitabine in Breast Cancer Chemotherapy
Author Information
Author(s): Wardley A M, Hiller L, Howard H C, Dunn J A, Bowman A, Coleman R E, Fernando I N, Ritchie D M, Earl H M, Poole C J
Primary Institution: Cancer Research UK
Hypothesis
Does the addition of gemcitabine to standard chemotherapy improve safety and tolerability in early breast cancer patients?
Conclusion
The addition of gemcitabine to chemotherapy for early breast cancer is safe and well tolerated, with only mild reductions in pulmonary function that recover by six months.
Supporting Evidence
- 88% of patients had normal FEV1 results.
- 81% of patients had normal FVC results.
- 56% of patients had normal TLCO results.
- Transient transaminitis occurred in both treatment arms.
- Only 11 patients had echocardiography/MUGA results change from normal to abnormal.
Takeaway
This study looked at how adding a medicine called gemcitabine to breast cancer treatment affects patients. It found that the treatment is safe and doesn't cause serious problems.
Methodology
Patients underwent assessments of cardiac, pulmonary, and hepatic function at four time points during and after chemotherapy.
Potential Biases
Potential bias in patient selection and reporting of adverse events.
Limitations
The study may not fully represent all breast cancer patients due to changes in eligibility criteria during recruitment.
Participant Demographics
{"age":{"≤50 years":69,">50 years":66},"ER_status":{"Negative":109,"Positive":15,"Unknown":11},"PgR_status":{"Negative":77,"Positive":5,"Unknown":42},"HER2_status":{"Positive":20,"Negative":31,"Unknown":79}}
Statistical Information
P-Value
{"TLCO":"P<0.0001","EC-GT":"P=0.02","AST":"P=0.03","ALT":"P=0.003"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website